Western Pharma Giants Paid Millions to Russian Distributors Linked to Fraud, Whistleblower Report Says

Nov. 2, 2026 A hospital in Moscow. Sergei Vedyashkin / Moskva News Agency Four major Western pharmaceutical companies paid tens of millions of dollars in unusually high bonuses to Russian middlemen to supply cancer drugs to state hospitals, according to whistleblower documents submitted to U.S. financial regulators. The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system. The pharmaceutical companies were alleged to have provided “excessive” sales bonuses and rebates ranging from 15% to 35% to Russian distributors, with the international average rarely exceeding 10%. The whistleblower report and other details were laid out in a joint investigation published Monday by the International Consortium of Investigative Journalists (ICIJ), the exiled Russian news outlet Proekt and the Swiss publication Republik. According to the report, Merck’s Russian distributor R-Pharma won $360 million in state contracts for the cancer drug Keytruda, winning 2,400 out of nearly 5,000 bids between 2020 and 2022. Procurement data reportedly showed 96% of the bids had no competitors, allowing sanctioned oligarch Alexei Repik’s R-Pharm to maintain a virtual monopoly on Keytruda supplies to state hospitals. R-Pharm CEO Vasily Ignatyev denied “any involvement” in improper payments or non-competitive practices, telling ICIJ that its commercial rebates were legitimate and defending Russia’s state auction procedures as transparent. Separately, Eli Lilly was alleged to have budgeted a 34% bonus for sales of its advanced cancer drug Cyramza in 2022. The year before, Moscow’s health department awarded more than $5 million in Cyramza contracts to distributor Pharmstandard, the sole bidder for most of those contracts. In another example, AstraZeneca’s drug Tagrisso was sold to Russian state hospitals at or above its official list price of at least $3,000 per box after single-participant bids in 95% of state tenders between 2020 and 2023. The company used distributor Pharmimex, which won $114.3 million out of nearly $129 million in state contracts for another drug, Koselugo, between 2022 and 2024 without competition. AstraZeneca, Merck and Eli Lilly either declined to comment or did not respond to requests from ICIJ for comment. Novartis, a Swiss multinational pharmaceutical corporation, was alleged to have identified examples of bid-rigging in government auctions for the drug Kisqali by distributors like Pharmimex and their affiliated front companies. A Novartis representative said the company conducted an internal investigation into the allegations without disclosing its findings. While the whistleblower reports do not contain direct financial records of bank transfers between distributors and officials, they allege that Western drugmakers were “willfully blind” to how their profit margins were being used. U.S. Foreign Corrupt Practices Act holds parent companies legally responsible for ignoring signs that third-party distributors are using company margins to fund kickbacks. The SEC and the Justice Department both declined to comment on the filings to ICIJ. Read more about: Business Sign up for our free weekly newsletter Our weekly newsletter contains a hand-picked selection of news, features, analysis and more from The Moscow Times. You will receive it in your mailbox every Friday. Never miss the latest news from Russia. Preview Subscribers agree to the Privacy Policy We sent a confirmation to your email. Please confirm your subscription. A Message from The Moscow Times: Dear readers, We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent." These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia. We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help. Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact. By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us. Once Monthly Annual Continue Not ready to support today? Remind me later. × Remind me next month Remind me Thank you! Your reminder is set. We will send you one reminder email a month from now. For details on the personal data we collect and how it is used, please see our Privacy Policy. Read more Russia’s Kamaz Sees Nearly Half of Output Shift to Defense Orders “Half of current production now goes on ‘black plates’,” one Kamaz dealer said, referring to military registration plates. 2 Min read Russian IT Wages Stagnate as Growth Falls Behind Inflation Rising prices have begun to erode real incomes for IT workers. 2 Min read Russia’s Northern Sea Route Cargo Volumes Fall for Second Straight Year Despite the Kremlin's plan to boost traffic along the Northern Sea Route, international demand remains limited due to a variety of factors. 2 Min read Ukrainian Strikes Cost Russian Oil Sector Over $13Bln in 2025, Insurers Say Bloomberg calculated that Ukraine carried out 120 attacks on Russian energy facilities in 2025. 2 Min read